Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Good morning, everyone. My name is Jess Fye, biotech analyst at JPMorgan, and we're continuing the 44th annual Morgan Healthcare Conference this morning with Alnylam. The company had a lot of update yesterday. I'm sure we'll talk about those.
We're going to start out with a presentation from the company's CEO, Yvonne Greenstreet. And then we're going to go into some Q&A. (Operator Instructions). But with that, let me pass it over to Yvonne.
Thank you, Jessica. Look, it's a real pleasure to be standing here as we launch this next exciting chapter in our Alnylam's history. I'm Yvonne Greenstreet, the CEO of Alnylam, and I'm delighted to be joined on stage here -- maybe stand back a bit -- by my colleagues, Pushkal Garg, our Chief R&D Officer; Tolga Tanguler, our Chief Commercial Officer, and Jeff Walton, our Chief Financial Officer. And of course, I'll be making forward-looking statements throughout my presentation.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
